Dr. Sagar Rakshit, MD

Dr. Rakshit practices at Schlanger, Gottlieb Partners Council Breast Imaging Center in Lake Success, New York.

Dr. Rakshit's NPI, 1528419181, was assigned on June 24, 2016. Dr. Rakshit holds North Dakota license 17978.

Dr. Rakshit's primary practice is Schlanger, Gottlieb Partners Council Breast Imaging Center, at 450 Lakeville Rd, Lake Success, NY 11042. The practice phone is (516) 734-8281.

Dr. Rakshit's primary practice is Schlanger, Gottlieb Partners Council Breast Imaging Center in Lake Success, New York. Dr. Rakshit is also affiliated with Long Island Jewish Medical Center. The medical group on file is Northwell Health Physician Partners. Dmand AI also links Dr. Rakshit to 3 more hospitals, 1 clinical lab and 1 group practice or clinic, each named with a free account. Dr. Rakshit's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rakshit practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Rakshit's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Rakshit's licenses on file in 2 states: North Dakota and Minnesota.

CMS data shows 884 Medicare services from Dr. Rakshit across 9 procedure codes in 2024, for 263 Medicare patients. Medicare paid $61,335 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 263 Medicare patients who saw Dr. Rakshit in 2024. The largest group is 65 to 74, with 137 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.99, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rakshit's median patient age at 75, with 51% women.

In 2024, Dr. Rakshit wrote 1,138 Medicare Part D claims for 155 patients. 79% of them were for generic drugs. CMS names the drug for 930 of them, across 32 drugs with 11 or more claims each, at $2,416,453 in total drug cost. In 2023, CMS named 657 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Rakshit for performance year 2024, reported as part of a group. Dr. Rakshit accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rakshit as offering telehealth.

Dmand AI links 18 papers to Dr. Rakshit, published from 2016 to 2023. 2017 was the busiest year, with 4. The most frequent topics are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms and Antibodies, Monoclonal. Dr. Rakshit has published most often in Clin Lung Cancer. Dr. Rakshit's most frequent co-authors are Vamsidhar Velcheti, MD, Robert C. Gilkeson, MD and Frank J. Jacono, MD.

CMS Open Payments shows 85 general payments to Dr. Rakshit from 34 drug and device companies from 2023 to 2025. Food and beverage make up the largest share, 95% of the total. Pfizer Inc. paid the most, $156.